Last reviewed · How we verify
A single "booster" dose of the Moderna mRNA COVID-19 vaccine
A single "booster" dose of the Moderna mRNA COVID-19 vaccine is a Standardized Insect Venom Allergenic Extract [EPC] Small molecule drug developed by Barbara Ann Karmanos Cancer Institute. It is currently FDA-approved. Also known as: Covid 19 booster dose.
At a glance
| Generic name | A single "booster" dose of the Moderna mRNA COVID-19 vaccine |
|---|---|
| Also known as | Covid 19 booster dose |
| Sponsor | Barbara Ann Karmanos Cancer Institute |
| Drug class | Standardized Insect Venom Allergenic Extract [EPC] |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- COVID-19 Booster Study in Healthy Adults in Australia (PHASE3)
- A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Vaccine Boosters (PHASE2)
- Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines (PHASE1, PHASE2)
- A Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 (COVID-19) Variants (PHASE2, PHASE3)
- Evaluation of Full Versus Fractional Doses of COVID-19 Vaccines Given as a Booster in Adults in Australia - Mongolia, Indonesia, Australia Coronavirus (MIACoV). (PHASE3)
- An Observational Study of Moderna COVID-19 Bivalent Vaccines (Original and Omicron BA.4/BA.5) and 2023 Updated mRNA COVID-19 Vaccines (XBB.1.5)
- A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19 (PHASE3)
- COVID-19 Fourth Dose Study in Australia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- A single "booster" dose of the Moderna mRNA COVID-19 vaccine CI brief — competitive landscape report
- A single "booster" dose of the Moderna mRNA COVID-19 vaccine updates RSS · CI watch RSS
- Barbara Ann Karmanos Cancer Institute portfolio CI
Frequently asked questions about A single "booster" dose of the Moderna mRNA COVID-19 vaccine
What is A single "booster" dose of the Moderna mRNA COVID-19 vaccine?
A single "booster" dose of the Moderna mRNA COVID-19 vaccine is a Standardized Insect Venom Allergenic Extract [EPC] drug developed by Barbara Ann Karmanos Cancer Institute.
Who makes A single "booster" dose of the Moderna mRNA COVID-19 vaccine?
A single "booster" dose of the Moderna mRNA COVID-19 vaccine is developed and marketed by Barbara Ann Karmanos Cancer Institute (see full Barbara Ann Karmanos Cancer Institute pipeline at /company/barbara-ann-karmanos-cancer-institute).
Is A single "booster" dose of the Moderna mRNA COVID-19 vaccine also known as anything else?
A single "booster" dose of the Moderna mRNA COVID-19 vaccine is also known as Covid 19 booster dose.
What drug class is A single "booster" dose of the Moderna mRNA COVID-19 vaccine in?
A single "booster" dose of the Moderna mRNA COVID-19 vaccine belongs to the Standardized Insect Venom Allergenic Extract [EPC] class. See all Standardized Insect Venom Allergenic Extract [EPC] drugs at /class/standardized-insect-venom-allergenic-extract-epc.
What development phase is A single "booster" dose of the Moderna mRNA COVID-19 vaccine in?
A single "booster" dose of the Moderna mRNA COVID-19 vaccine is FDA-approved (marketed).
Related
- Drug class: All Standardized Insect Venom Allergenic Extract [EPC] drugs
- Manufacturer: Barbara Ann Karmanos Cancer Institute — full pipeline
- Also known as: Covid 19 booster dose
- Compare: A single "booster" dose of the Moderna mRNA COVID-19 vaccine vs similar drugs
- Pricing: A single "booster" dose of the Moderna mRNA COVID-19 vaccine cost, discount & access